BioMarin Pharmaceutical Inc.
BMRNNASDAQHealthcare● Active
$56.31
$-0.47(-0.82%)
Market Cap$10.9B
P/E Ratio—
52W High$66.28
52W Low$49.26
BioMarin Pharmaceutical Inc. (BMRN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BMRN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Cost of Revenue | $0.74B | $0.58B | $0.53B | $0.50B | $0.47B |
| Gross Profit | $2.48B | $2.27B | $1.89B | $1.59B | $1.38B |
| Gross Margin %(computed) | 77.13% | 79.67% | 78.01% | 76.00% | 74.52% |
| Operating Expenses | |||||
| R&D Expenses | $0.92B | $0.75B | $0.75B | $0.65B | $0.63B |
| G&A Expenses | $1.15B | $0.53B | $0.40B | $0.37B | $0.35B |
| Total Operating Expenses | $1.95B | $1.79B | $1.70B | $1.43B | $1.46B |
| Operating Income | $0.53B | $0.48B | $0.19B | $0.16B | ($0.08B) |
| Operating Margin %(computed) | 16.56% | 16.97% | 7.68% | 7.68% | -4.46% |
| Interest Income | $0.07B | $0.07B | $0.06B | $0.02B | $0.01B |
| Interest Expense | $0.01B | $0.01B | $0.02B | $0.02B | $0.02B |
| Income Before Tax | $0.48B | $0.54B | $0.19B | $0.15B | ($0.08B) |
| Income Tax Expense | $0.13B | $0.11B | $0.02B | $0.01B | ($0.01B) |
| Net Income | $0.35B | $0.43B | $0.17B | $0.14B | ($0.06B) |
| Net Margin %(computed) | 10.83% | 14.96% | 6.93% | 6.75% | -3.47% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 |
| Wtd Avg Shares | 0.19B | 0.19B | 0.19B | 0.19B | 0.18B |
| EBITDA | $0.57B | $0.65B | $0.31B | $0.27B | $0.05B |
| EBITDA Margin %(computed) | 17.79% | 22.79% | 12.68% | 12.66% | 2.57% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more BioMarin Pharmaceutical Inc. data
About BioMarin Pharmaceutical Inc. (BMRN) Income Statement
BioMarin Pharmaceutical Inc. (BMRN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BMRN reported revenue of $3.22B, gross profit of $2.48B (gross margin 77.13%), and net income of $0.35B — a net profit margin of 10.83%.
Frequently asked questions
BMRN · 4 questionsBioMarin Pharmaceutical Inc. (BMRN) reported revenue of $3.22B for 2025, up 12.9% year-over-year.
BMRN revenueBMRN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08